|  Help  |  About  |  Contact Us

Publication : Rapamycin prevents retinal neovascularization by downregulation of cyclin D1 in a mouse model of oxygen-induced retinopathy.

First Author  Jiang F Year  2020
Journal  BMC Ophthalmol Volume  20
Issue  1 Pages  44
PubMed ID  32013948 Mgi Jnum  J:298405
Mgi Id  MGI:6480082 Doi  10.1186/s12886-020-1325-5
Citation  Jiang F, et al. (2020) Rapamycin prevents retinal neovascularization by downregulation of cyclin D1 in a mouse model of oxygen-induced retinopathy. BMC Ophthalmol 20(1):44
abstractText  BACKGROUND: Rapamycin (RAPA) is a potent angiogenic inhibitor and the aim of this study is to identify the inhibitory effect of RAPA on retinal neovascularization (RNV) in experimental oxygen-induced retinopathy (OIR). METHODS: Forty-two 7-day-old C57BL/6 J mice were randomly divided into normoxia control group (14 mice), OIR group (14 mice), and rapamycin (RAPA) group. OIR model was induced in OIR and RAPA group. Vehicle and RAPA (2 mg/kg/d) was injected intraperitoneally daily from postnatal day 12 (P12) in OIR and RAPA groups, respectively. RNV was evaluated using fluorescence angiography and histopathology on P17. Non-perfused areas of retina were analyzed by Image-Pro plus 6.0 software. Retinal expression of cyclin D1 was detected both at mRNA and protein levels. RESULTS: RAPA treatment significantly decreased RNV, non-perfused areas and number of endothelial cell nuclei breaking through the internal limiting membrane (ILM) in OIR mice. Moreover, RAPA decreased activation of cyclin D1 in retina caused by OIR. CONCLUSION: RAPA can inhibit RNV by downregulating the expression of cyclin D1, which indicates its therapeutic potential in treating RNV-related diseases.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

5 Authors

1 Bio Entities

0 Expression